PVRIG的抗体或其抗原结合片段及其应用
By developing antibodies or antigen-binding fragments that specifically recognize PVRIG, the PVRIG/CD112 signaling pathway is blocked, which solves the problem of T cell and NK cell immunosuppression and enhances the efficacy of tumor immunotherapy, especially for cancer patients.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HEFEI TG IMMUNOPHARMA CO LTD
- Filing Date
- 2021-12-24
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are unable to effectively block the binding of PVRIG to CD112, leading to immunosuppression of T cells and NK cells and affecting the efficacy of tumor immunotherapy.
Develop antibodies or antigen-binding fragments that can specifically recognize PVRIG and enhance the killing effect of lymphocytes by blocking the PVRIG/CD112 signaling pathway. This includes the design of specific CDR sequences and amino acid sequences, combined with the application of nucleic acid molecules, expression vectors, and recombinant cells.
It enhances the killing function of T cells and NK cells, improves the efficacy of tumor immunotherapy, and significantly inhibits tumor growth, especially when used in combination with other immune checkpoint inhibitors.
Smart Images
Figure HDA0003432588580000011 
Figure HDA0003432588580000012 
Figure HDA0003432588580000021